Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
PBYI Puma Biotechnology	$4.99 -3.5%	$5.70	$2.13 ▼ $7.73	$240.57M	1.28	573,195 shs	289,054 shs
RVLP RVL Pharmaceuticals		$0.04	$0.03 ▼ $1.91	N/A	N/A	N/A	63.96 million shs
VHAQ Viveon Health Acquisition	$9.00	$8.64	$0.00 ▼ $12.48	$59.84M	-0.02	1 shs	8 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PBYI Puma Biotechnology	-3.48%	-9.11%	+16.05%	+5.94%	+80.14%
RVLP RVL Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-97.18%
VHAQ Viveon Health Acquisition	0.00%	0.00%	+499,900.00%	-19.79%	-18.40%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	2.5156 of 5 stars	3.5	2.0	0.0	0.0	1.3	3.3	1.3
RVLP RVL Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	3.00	Buy	$7.00	40.28% Upside
RVLP RVL Pharmaceuticals	3.00	Buy	$2.50	∞ Upside
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OPNT, PBYI, VHAQ, and RVLP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/1/2024	PBYI Puma Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
2/13/2024	PBYI Puma Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
PBYI Puma Biotechnology	$235.60M	1.02	$0.68 per share	7.33	$1.12 per share	4.46
RVLP RVL Pharmaceuticals	$49.72M	0.00	N/A	N/A	$0.51 per share	0.00
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	($3.22) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
PBYI Puma Biotechnology	$21.59M	$0.46	10.85	17.21	2.90	9.16%	58.21%	10.40%	5/2/2024 (Estimated)
RVLP RVL Pharmaceuticals	-$51.69M	-$0.70	0.00	N/A	N/A	N/A	N/A	N/A	5/9/2024 (Estimated)
VHAQ Viveon Health Acquisition	-$610K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OPNT, PBYI, VHAQ, and RVLP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	PBYI Puma Biotechnology	$0.33	$0.26	-$0.07	$0.26	$73.22 million	$72.20 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
RVLP RVL Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
PBYI Puma Biotechnology	1.23	1.57	1.50
RVLP RVL Pharmaceuticals	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
OPNT Opiant Pharmaceuticals	42.39%
PBYI Puma Biotechnology	61.29%
RVLP RVL Pharmaceuticals	14.36%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
OPNT Opiant Pharmaceuticals	25.15%
PBYI Puma Biotechnology	22.70%
RVLP RVL Pharmaceuticals	4.40%
VHAQ Viveon Health Acquisition	75.27%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
PBYI Puma Biotechnology	185	48.21 million	37.26 million	Optionable
RVLP RVL Pharmaceuticals	125	111.41 million	106.50 million	Optionable
VHAQ Viveon Health Acquisition	N/A	6.65 million	1.64 million	Not Optionable

OPNT, PBYI, VHAQ, and RVLP Headlines

Source	Headline
	Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process finanznachrichten.de - February 28 at 3:42 PM
	VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS globenewswire.com - February 27 at 4:45 PM
	NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ) finance.yahoo.com - February 21 at 7:40 PM
	Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE finance.yahoo.com - December 27 at 7:32 PM
	NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ) tmcnet.com - December 22 at 6:29 PM
	San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas. finance.yahoo.com - November 13 at 8:17 PM
	NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS) finance.yahoo.com - October 24 at 12:34 PM
	VHAQ-R Viveon Health Acquisition Corp. seekingalpha.com - September 23 at 7:56 AM
	Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation marketwatch.com - September 15 at 6:11 PM
	VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION finance.yahoo.com - September 15 at 6:11 PM
	Viveon Healthcare Increases Consideration Offered to Clearday Shareholders finance.yahoo.com - September 5 at 6:45 PM
	SPAC Viveon ups merger consideration for Clearday to $500M msn.com - August 29 at 4:18 PM
	Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement finance.yahoo.com - August 29 at 4:18 PM
	VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING finance.yahoo.com - April 25 at 9:05 PM
	Viveon Health Acquisition Corp. (VHAQ-RT) finance.yahoo.com - April 18 at 3:32 PM
	(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market finance.yahoo.com - April 12 at 12:15 PM
	SPAC Viveon to merge with senior-care tech provider Clearday seekingalpha.com - April 6 at 1:59 PM
	SPAC Viveon signs merger LOI with health monitoring platform Clearday msn.com - March 1 at 2:48 PM
	Viveon Health Acquisition Corp. and Clearday Inc. Announce Signed Letter of Intent to Merge and Create a Leading Longevity Care Company finance.yahoo.com - March 1 at 9:48 AM
	SPAC Viveon terminates planned merger with Suneva Medical msn.com - February 6 at 6:48 PM
	Viveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc. finance.yahoo.com - February 3 at 12:53 PM
	VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with ... kentuckytoday.com - January 27 at 10:07 AM
	SPAC Viveon Health delays Suneva merger vote amid cash issues msn.com - January 25 at 2:25 PM
	VIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Until February 3, 2023. finance.yahoo.com - January 25 at 2:25 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Opiant Pharmaceuticals

NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Puma Biotechnology

NASDAQ:PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

RVL Pharmaceuticals

NASDAQ:RVLP

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Viveon Health Acquisition

NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial